

DEBLASI UGO D

Form 4

October 10, 2006

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
*See Instruction*  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
DEBLASI UGO D

(Last) (First) (Middle)

APPLERA CORPORATION, 301  
MERRITT 7

(Street)

NORWALK, CT 06851-1070

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
Symbol  
APPLERA CORP [ABI/CRA]

3. Date of Earliest Transaction  
(Month/Day/Year)  
10/08/2006

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_ 10% Owner  
☒ Officer (give title below) \_\_\_\_ Other (specify  
below) below)

Vice President and Controller

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of<br>Security<br>(Instr. 3)             | 2. Transaction Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 3. Transaction<br>Code<br>(Instr. 8) | 4. Securities Acquired<br>(A) or Disposed of (D)<br>(Instr. 3, 4 and 5) | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 3 and 4) | 6. Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I)<br>(Instr. 4) | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------------------------|-----------------------------------------|-------------------------------------------------------------|--------------------------------------|-------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------|
| Applied<br>Biosystems<br>Group<br>Common<br>Stock | 10/08/2006                              |                                                             | M                                    | 1,162 A                                                                 | \$<br>33.405 6,120.9205<br>(1)                                                                                     | D                                                                       |                                                                   |
| Applied<br>Biosystems<br>Group<br>Common<br>Stock | 10/08/2006                              |                                                             | D                                    | 1,162 D                                                                 | \$<br>33.405 4,958.9205<br>(1)                                                                                     | D                                                                       |                                                                   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3)               | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|----------------------------------------------------------|--------------------------------------------------------|--------------------------------------|----------------------------------------------------|--------------------------------|-----------------------------------------------------------------------------------------|----------------------------------------------------------|---------------------------------------------------------------|
| Applied Biosystems Group Series FY03-4 Performance Units | (2)                                                    | 10/08/2006                           |                                                    | M                              | 2,500 (3)                                                                               | (2) 03/24/2013                                           | Applied Biosystems Group Common Stock (2)                     |

## Reporting Owners

| Reporting Owner Name / Address                                                  | Relationships |           |                               |       |
|---------------------------------------------------------------------------------|---------------|-----------|-------------------------------|-------|
|                                                                                 | Director      | 10% Owner | Officer                       | Other |
| DEBLASI UGO D<br>APPLERA CORPORATION<br>301 MERRITT 7<br>NORWALK, CT 06851-1070 |               |           | Vice President and Controller |       |

## Signatures

/s/ Thomas P. Livingston, Attorney-In-Fact for Ugo D.  
DeBlasi

10/10/2006

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Represents settlement of Performance Units for cash as described in footnote 3 below. Price listed is the fair market value of Applera Corporation - Applied Biosystems Group Common Stock ("ABI Stock") on the settlement date. The settlement date was a Sunday, and therefore, the fair market value on the settlement date is based on the trading price of ABI Stock on October 6, 2006, the last trading date prior to the settlement date.

## Edgar Filing: DEBLASI UGO D - Form 4

The Performance Units provide for payment upon ABI Stock attaining price targets of \$26.79 and \$32.04 per share for a specified period  
(2) and are payable over a minimum of eight quarters, subject to continued employment and an aggregate program expense cap. Units are payable in cash equal to \$15.54 for each Performance Unit.

(3) Represents the payment of 2,500 Performance Units upon attainment of the \$32.04 price target described in footnote 2 above.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.